Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Terminated 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 81CNS 15Sarcoma 8Tumor-Agnostic 7Thoracic 5Other solid neoplasm 5Gynecologic 4Genitourinary 4Breast 3Lymphoid 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neoplasms, Basal Cell 1

Interventions

pembrolizumab 65Nivolumab 58Ipilimumab 32Cyclophosphamide 22Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13cemiplimab 13fludarabine 12Opdualag 12binimetinib 10Blood Specimen Collection 10aldesleukin 9Radiosurgery 9encorafenib 8Interleukin-2 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Radiotherapy 5Disulfides 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Irinotecan × Dermatologic × Clear all
NCT06483555 2026-04-23

PANGEA

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
104 enrolled
DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡